SironRX, a US-based healthcare company developing better bandages, has raised $500,000 from Cleveland Clinic Innovations, the corporate venturing unit of a local medical centre, and non-profit venture incubator JumpStart.
SironRX spun out from Juventas Therapeutics and licenses products from its parent and Cleveland Clinic and will use the funds to initiate a phase II clinical study of its lead product.
Marc Penn, director of the Skirball Cardiovascular Cell Therapy Laboratory at Cleveland Clinic, is chief scientific officer at SironRX.